Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Basic Helix-Loop-Helix Transcription Factors* ; Neoplasm Proteins* ; Receptors, Odorant*; Biomarkers, Tumor/*blood ; Bone Neoplasms/*blood ; MicroRNAs/*blood ; Prostatic Neoplasms/*blood ; RNA, Messenger/*blood ; RNA, Neoplasm/*blood; Aged ; Bone Neoplasms/pathology ; Bone Neoplasms/secondary ; Bone Neoplasms/therapy ; Humans ; Kallikreins/blood ; Male ; Middle Aged ; Neoplasm Metastasis ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/therapy ; Reverse Transcriptase Polymerase Chain Reaction

Circulating nucleic acids are found in free form in body fluids and may serve as minimally invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the potential application of circulating mRNAs and microRNAs (miRNAs) in prostate cancer (PCa). The Cancer Genome Atlas (TCGA) database was used for an in silico analysis to identify circulating mRNA and miRNA as potential markers of PCa. A total of 2,267 genes and 49 miRNAs were differentially expressed between normal and tumor samples. The prediction analyses of target genes and integrative analysis of mRNA and miRNA expression revealed eleven genes and eight miRNAs which were validated by RT-qPCR in plasma samples from 102 untreated PCa patients and 50 cancer-free individuals. Two genes, OR51E2 and SIM2, and two miRNAs, miR-200c and miR-200b, showed significant association with PCa. Expression levels of these transcripts distinguished PCa patients from controls (67% sensitivity and 75% specificity). PCa patients and controls with prostate-specific antigen (PSA) ≤ 4.0 ng/mL were discriminated based on OR51E2 and SIM2 expression levels. The miR-200c expression showed association with Gleason score and miR-200b, with bone metastasis, bilateral tumor, and PSA > 10.0 ng/mL. The combination of circulating mRNA and miRNA was useful for the diagnosis and prognosis of PCa.

PLoS One. 2013 Jul 30;8(7):e69239. (PMID: 23935962)
Tumour Biol. 2011 Jun;32(3):583-8. (PMID: 21274675)
PLoS One. 2014 Nov 19;9(11):e113700. (PMID: 25409297)
Theranostics. 2017 Mar 24;7(6):1407-1421. (PMID: 28529626)
Genes Dev. 2010 Sep 15;24(18):1967-2000. (PMID: 20844012)
Int J Cancer. 2012 Feb 1;130(3):611-21. (PMID: 21400514)
Oncol Rep. 2014 Feb;31(2):910-8. (PMID: 24317363)
Nat Rev Cancer. 2011 Jun;11(6):426-37. (PMID: 21562580)
Adv Drug Deliv Rev. 2015 Jan;81:75-93. (PMID: 25220354)
BMC Cancer. 2015 Nov 18;15:915. (PMID: 26582057)
N Engl J Med. 2004 May 27;350(22):2239-46. (PMID: 15163773)
Med Oncol. 2012 Jun;29(2):815-22. (PMID: 21487968)
Cancer Cell Int. 2016 Feb 19;16:12. (PMID: 26900347)
DNA Cell Biol. 2015 Mar;34(3):189-200. (PMID: 25521481)
N Engl J Med. 2012 Mar 15;366(11):981-90. (PMID: 22417251)
Int J Cancer. 2015 Sep 15;137(6):1406-16. (PMID: 25754273)
Lab Invest. 2005 Jan;85(1):154-9. (PMID: 15543203)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Prostate. 2012 Sep 15;72(13):1469-77. (PMID: 22298119)
Mol Oncol. 2012 Dec;6(6):590-610. (PMID: 23102669)
Prostate. 2008 Oct 1;68(14):1555-60. (PMID: 18651557)
PLoS One. 2013 Dec 31;8(12):e83991. (PMID: 24391862)
Ann Intern Med. 2012 Jul 17;157(2):120-34. (PMID: 22801674)
Clin Chim Acta. 2010 Oct 9;411(19-20):1452-6. (PMID: 20573596)
Cancer. 2014 Nov 15;120(22):3519-26. (PMID: 25065910)
PLoS One. 2011;6(6):e20769. (PMID: 21698099)
Curr Treat Options Oncol. 2013 Mar;14(1):97-108. (PMID: 23318986)
Br J Cancer. 2012 Feb 14;106(4):768-74. (PMID: 22240788)
Urol Oncol. 2013 Jul;31(5):566-71. (PMID: 21600800)
Mol Cancer. 2016 May 18;15(1):41. (PMID: 27189160)
Molecules. 2015 Oct 20;20(10):19030-40. (PMID: 26492230)
Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47. (PMID: 26590260)
Lab Invest. 2001 May;81(5):767-9. (PMID: 11351048)
PLoS One. 2012;7(8):e43470. (PMID: 22916267)
Am J Pathol. 2012 Dec;181(6):2188-201. (PMID: 23041061)
J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. (PMID: 19720969)
Clin Chem. 2009 Apr;55(4):611-22. (PMID: 19246619)
FEBS Lett. 2007 Mar 6;581(5):795-9. (PMID: 17289032)
Int J Mol Sci. 2016 Oct 26;17 (11):. (PMID: 27792187)
PLoS One. 2011;6(12):e28837. (PMID: 22174909)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Int J Cancer. 2011 Feb 1;128(3):608-16. (PMID: 20473869)
Eur Urol. 2016 Aug;70(2):312-22. (PMID: 26806656)
Clin Cancer Res. 2009 Sep 15;15(18):5794-802. (PMID: 19737960)
Prostate. 2010 Dec 1;70(16):1760-7. (PMID: 20672322)
PLoS One. 2013 Dec 11;8(12):e83025. (PMID: 24349425)
Eur Urol. 2015 Jan;67(1):33-41. (PMID: 25129854)
Br J Cancer. 2017 Jan 3;116(1):141-148. (PMID: 27855442)
BMC Cancer. 2014 Feb 11;14:82. (PMID: 24517338)
J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. (PMID: 22228146)
Cancer Res. 2000 Dec 1;60(23):6568-72. (PMID: 11118034)
Oncogenesis. 2014 Aug 11;3:e114. (PMID: 25111863)
PLoS One. 2015 Jun 02;10(6):e0128642. (PMID: 26035744)
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56. (PMID: 24492836)
Nat Methods. 2015 Aug;12(8):697. (PMID: 26226356)
Comput Struct Biotechnol J. 2016 Jun 01;14:211-22. (PMID: 27358717)
Prostate. 2013 Jul;73(10 ):1048-56. (PMID: 23389960)
Clin Cancer Res. 2007 Feb 1;13(3):892-7. (PMID: 17289882)
PLoS One. 2015 Apr 14;10(4):e0124245. (PMID: 25874774)
Mutat Res. 1988 Mar;204(3):379-406. (PMID: 3347212)
Cancer Inform. 2007 Feb 04;3:11-7. (PMID: 19455231)
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4760-5. (PMID: 12676991)
Int J Biochem Cell Biol. 2004 Feb;36(2):189-204. (PMID: 14643885)
Tumour Biol. 2014 Dec;35(12):12613-7. (PMID: 25190021)
Nat Rev Urol. 2010 Sep;7(9):487-93. (PMID: 20818326)
Prostate. 2015 Jul 1;75(10):1102-13. (PMID: 25845829)

0 (Basic Helix-Loop-Helix Transcription Factors)
0 (Biomarkers, Tumor)
0 (MIRN200 microRNA, human)
0 (MicroRNAs)
0 (Neoplasm Proteins)
0 (OR51E2 protein, human)
0 (RNA, Messenger)
0 (RNA, Neoplasm)
0 (Receptors, Odorant)
0 (SIM2 protein, human)
EC 3.4.21.- (KLK3 protein, human)
EC 3.4.21.- (Kallikreins)
EC 3.4.21.77 (Prostate-Specific Antigen)

Date Created: 20170915 Date Completed: 20171012 Latest Revision: 20220410

20240513

PMC5598937

10.1371/journal.pone.0184094

28910345